Welcome to: Rimonabant Information Source (rimonabant fraud)

buy Rimonabant and lose weight
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 

Effective weight loss with Rimonabant

Diet pill rimonabant (also know as Acomplia / Zimulti), which is approved for use in Europe and some other countries, but not the United States, may be useful in blocking the development of alcoholic fatty liver, according USresearchers. Reporting in the March edition of the journal Cell Metabolism, the researchers from the National Institute on Alcohol Abuse and Alcoholism found that mice treated with rimonabant, a pill for blocking cannabino? Receptors in the brains are resistant to alcohol the fat-building effects in the liver. Alcoholic fatty liver is a reason for more serious disease, and alcoholism is a leading cause of liver disease in the U.

Rimonabant Pricelist

Please wait while we load the price list
Rimonabant is an anorectic anti-obesity drug. It works by suppressing our appetite making the stomach feel full. It is a cannabinoid receptor antagonist which blocks a special type of receptors called the CB1 receptors found in the nervous system. On the other hand, it is found that it also acts as smoking cessation agent. It is developed from the knowledge that cannabis smokers often experience extreme hunger ripples. So, researchers worked on the premise that if cannabinoid stimulates appetite, blocking cannabinoid receptors in the brain might control the smoking urge found in smokers. Hence it is said that Rimonabant can be very effective in controlling one's smoking habit. Though a new entrant in the weight loss market, it is creating waves for its dual nature and efficacy. Besides, no serious adverse effects are detected till date.

People who take the weight-loss drug rimonabant may face heightened risks for severe depression and anxiety, Danish researchers report. The finding follows a recommendation by a U. S. Food and Drug Administration panel in June that the agency not approve the diet drug because of continuing concerns about increased risks for suicidal thoughts among some users. Previously, the FDA rejected the drug as an aid to help people quit smoking."Up to this point in time, there has been controversy over the rates and severity of psychiatric adverse effects with rimonabant," noted Dr. Philip Mitchell, head of the School of Psychiatry at the University of New South Wales in Sydney, Australia, and co-author of an editorial that accompanies the study.